Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.51 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.51 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.51 |
| ▸ | CBFB | Q13951 | 1/20 | 0.51 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.51 |
| ▸ | FEN1 | P39748 | 2/20 | 0.51 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005991 | 0.78 | MAOA (0.64) | MAOAKDM4EKMT2AMEN1NPC1 | |
| SCHEMBL13135962 | 0.78 | MAOA (0.64) | MAOAKDM4EKMT2AMEN1NPC1 | |
| SCHEMBL14399200 | 0.78 | HPGD (0.63) | MAOAKDM4EKMT2AGLAERCC1 | |
| SCHEMBL29865102 | 0.78 | EIF4A3 (0.55) | KDM4EKMT2AMEN1NPC1GLA | |
| SCHEMBL3033200 | 0.78 | EIF4A3 (0.55) | KDM4EKMT2AMEN1NPC1GLA | |
| SCHEMBL15043776 | 0.77 | CA12 (0.47) | KDM4ENPC1MAPTRAB9AHPGD | |
| Acedoben SCHEMBL28207589 | 0.77 | CA12 (0.53) | MAOAKDM4EKMT2AMEN1NPC1 | |
| SCHEMBL6740302 | 0.76 | MEN1 (0.69) | KDM4EKMT2AMEN1MAPTRAB9A | |
| SCHEMBL8577441 | 0.76 | MEN1 (0.68) | KDM4EKMT2AMEN1NPC1GLA | |
| SCHEMBL11857777 | 0.75 | KIF11 (0.51) | MAPTTP53LMNAKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1632477-B1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2017-03-01 | — | — | EP | disclosed |
| EP-1632477-B1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-7855198-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855198-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| CN-100562513-C | Benzamide derivatives or its salt | ASTELLAS PHARMA INC (JP) | 2009-11-25 | — | — | CN | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20070167444-A1 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. | 2007-07-19 | — | — | US | disclosed |
| CN-1805923-A | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2006-07-19 | — | — | CN | disclosed |
| EP-1632477-A1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | TRPV1, TRPV2, TRPV3 | MAOA 1628/4885KDM4E 1484/4885KMT2A 1040/4885 |
| US-20070167444-A1 | Benzamide derivative or salt thereof | TRPV1, BDKRB1, BDKRB2 | MAOA 1329/4885KDM4E 2143/4885KMT2A 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.